Marktanalyse - Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016

Global Markets Direct
12.2016
1093 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) — Pipeline Review, H2 2016, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 61, 60, 2, 114, 22 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 8, 18 and 6 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 9

Multiple Myeloma (Kahler Disease) Overview 10

Therapeutics Development 11

Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies 13

Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes 27

Multiple Myeloma (Kahler Disease) - Pipeline Products Glance 29

Multiple Myeloma (Kahler Disease) - Products under Development by Companies 33

Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes 57

Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development 60

Multiple Myeloma (Kahler Disease) - Therapeutics Assessment 208

Drug Profiles 261

Multiple Myeloma (Kahler Disease) - Dormant Projects 1022

Multiple Myeloma (Kahler Disease) - Discontinued Products 1048

Multiple Myeloma (Kahler Disease) - Product Development Milestones 1053

Appendix 1060





List of Tables

Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2016 43

Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H2 2016 44

Number of Products under Development by Companies, H2 2016 46

Number of Products under Development by Companies, H2 2016 (Contd..1) 47

Number of Products under Development by Companies, H2 2016 (Contd..2) 48

Number of Products under Development by Companies, H2 2016 (Contd..3) 49

Number of Products under Development by Companies, H2 2016 (Contd..4) 50

Number of Products under Development by Companies, H2 2016 (Contd..5) 51

Number of Products under Development by Companies, H2 2016 (Contd..6) 52

Number of Products under Development by Companies, H2 2016 (Contd..7) 53

Number of Products under Development by Companies, H2 2016 (Contd..8) 54

Number of Products under Development by Companies, H2 2016 (Contd..9) 55

Number of Products under Development by Companies, H2 2016 (Contd..10) 56

Number of Products under Development by Companies, H2 2016 (Contd..11) 57

Number of Products under Development by Companies, H2 2016 (Contd..12) 58

Number of Products under Investigation by Universities/Institutes, H2 2016 59

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 60

Comparative Analysis by Late Stage Development, H2 2016 61

Comparative Analysis by Clinical Stage Development, H2 2016 62

Comparative Analysis by Early Stage Development, H2 2016 63

Comparative Analysis by Unknown Stage Development, H2 2016 64

Products under Development by Companies, H2 2016 65

Products under Development by Companies, H2 2016 (Contd..1) 66

Products under Development by Companies, H2 2016 (Contd..2) 67

Products under Development by Companies, H2 2016 (Contd..3) 68

Products under Development by Companies, H2 2016 (Contd..4) 69

Products under Development by Companies, H2 2016 (Contd..5) 70

Products under Development by Companies, H2 2016 (Contd..6) 71

Products under Development by Companies, H2 2016 (Contd..7) 72

Products under Development by Companies, H2 2016 (Contd..8) 73

Products under Development by Companies, H2 2016 (Contd..9) 74

Products under Development by Companies, H2 2016 (Contd..10) 75

Products under Development by Companies, H2 2016 (Contd..11) 76

Products under Development by Companies, H2 2016 (Contd..12) 77

Products under Development by Companies, H2 2016 (Contd..13) 78

Products under Development by Companies, H2 2016 (Contd..14) 79

Products under Development by Companies, H2 2016 (Contd..15) 80

Products under Development by Companies, H2 2016 (Contd..16) 81

Products under Development by Companies, H2 2016 (Contd..17) 82

Products under Development by Companies, H2 2016 (Contd..18) 83

Products under Development by Companies, H2 2016 (Contd..19) 84

Products under Development by Companies, H2 2016 (Contd..20) 85

Products under Development by Companies, H2 2016 (Contd..21) 86

Products under Development by Companies, H2 2016 (Contd..22) 87

Products under Development by Companies, H2 2016 (Contd..23) 88

Products under Investigation by Universities/Institutes, H2 2016 89

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 90

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 91

Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H2 2016 92

Multiple Myeloma (Kahler Disease) - Pipeline by AB Science SA, H2 2016 93

Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H2 2016 94

Multiple Myeloma (Kahler Disease) - Pipeline by Ablynx NV, H2 2016 95

Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma Inc, H2 2016 96

Multiple Myeloma (Kahler Disease) - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 97

Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 98

Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H2 2016 99

Multiple Myeloma (Kahler Disease) - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 100

Multiple Myeloma (Kahler Disease) - Pipeline by ADC Therapeutics Sarl, H2 2016 101

Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H2 2016 102

Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 103

Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H2 2016 104

Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H2 2016 105

Multiple Myeloma (Kahler Disease) - Pipeline by Alissa Pharma, H2 2016 106

Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corp, H2 2016 107

Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H2 2016 108

Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals Inc, H2 2016 109

Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H2 2016 110

Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H2 2016 111

Multiple Myeloma (Kahler Disease) - Pipeline by Arcarios BV, H2 2016 112

Multiple Myeloma (Kahler Disease) - Pipeline by Arno Therapeutics Inc, H2 2016 113

Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc, H2 2016 114

Multiple Myeloma (Kahler Disease) - Pipeline by Arvinas Inc, H2 2016 115

Multiple Myeloma (Kahler Disease) - Pipeline by Asana BioSciences LLC, H2 2016 116

Multiple Myeloma (Kahler Disease) - Pipeline by Astellas Pharma Inc, H2 2016 117

Multiple Myeloma (Kahler Disease) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 118

Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H2 2016 119

Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H2 2016 120

Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 121

Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H2 2016 122

Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 123

Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 124

Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H2 2016 125

Multiple Myeloma (Kahler Disease) - Pipeline by bluebird bio Inc, H2 2016 126

Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H2 2016 127

Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Company, H2 2016 128

Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences Inc, H2 2016 129

Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H2 2016 130

Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H2 2016 131

Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences Inc, H2 2016 132

Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis SA, H2 2016 133

Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics Inc, H2 2016 134

Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H2 2016 135

Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H2 2016 136

Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H2 2016 137

Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 138

Multiple Myeloma (Kahler Disease) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 139

Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Biosciences Inc, H2 2016 140

Multiple Myeloma (Kahler Disease) - Pipeline by Constellation Pharmaceuticals Inc, H2 2016 141

Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H2 2016 142

Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 143

Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 144

Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H2 2016 145

Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Company, H2 2016 146

Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H2 2016 147

Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis Inc, H2 2016 148

Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 149

Multiple Myeloma (Kahler Disease) - Pipeline by Five Prime Therapeutics Inc, H2 2016 150

Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd, H2 2016 151

Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science srl, H2 2016 152

Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H2 2016 153

Multiple Myeloma (Kahler Disease) - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016 154

Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik Inc, H2 2016 155

Multiple Myeloma (Kahler Disease) - Pipeline by GlycoMimetics Inc, H2 2016 156

Multiple Myeloma (Kahler Disease) - Pipeline by GlyTR Therapeutics Inc, H2 2016 157

Multiple Myeloma (Kahler Disease) - Pipeline by GP Pharm SA, H2 2016 158

Multiple Myeloma (Kahler Disease) - Pipeline by Heidelberg Pharma GmbH, H2 2016 159

Multiple Myeloma (Kahler Disease) - Pipeline by Hutchison MediPharma Ltd, H2 2016 160

Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology LLC, H2 2016 161

Multiple Myeloma (Kahler Disease) - Pipeline by ImmunGene Inc, H2 2016 162

Multiple Myeloma (Kahler Disease) - Pipeline by Immunomedics Inc, H2 2016 163

Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corp, H2 2016 164

Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Ltd, H2 2016 165

Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H2 2016 166

Multiple Myeloma (Kahler Disease) - Pipeline by Jasco Pharmaceuticals LLC, H2 2016 167

Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H2 2016 168

Multiple Myeloma (Kahler Disease) - Pipeline by Juno Therapeutics Inc, H2 2016 169

Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corp, H2 2016 170

Multiple Myeloma (Kahler Disease) - Pipeline by Kancera AB, H2 2016 171

Multiple Myeloma (Kahler Disease) - Pipeline by Karus Therapeutics Ltd, H2 2016 172

Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 173

Multiple Myeloma (Kahler Disease) - Pipeline by Kesios Therapeutics Ltd, H2 2016 174

Multiple Myeloma (Kahler Disease) - Pipeline by Kite Pharma Inc, H2 2016 175

Multiple Myeloma (Kahler Disease) - Pipeline by LG Life Science LTD, H2 2016 176

Multiple Myeloma (Kahler Disease) - Pipeline by MediGene AG, H2 2016 177

Multiple Myeloma (Kahler Disease) - Pipeline by MedImmune LLC, H2 2016 178

Multiple Myeloma (Kahler Disease) - Pipeline by Medivation Inc, H2 2016 179

Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co Inc, H2 2016 180

Multiple Myeloma (Kahler Disease) - Pipeline by Mesoblast Ltd, H2 2016 181

Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 182

Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax LLC, H2 2016 183

Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H2 2016 184

Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H2 2016 185

Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H2 2016 186

Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H2 2016 187

Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co Ltd, H2 2016 188

Multiple Myeloma (Kahler Disease) - Pipeline by Nordic Nanovector ASA, H2 2016 189

Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H2 2016 190

Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H2 2016 191

Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H2 2016 192

Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc, H2 2016 193

Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics Inc, H2 2016 194

Multiple Myeloma (Kahler Disease) - Pipeline by OncoPep Inc, H2 2016 195

Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H2 2016 196

Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 197

Multiple Myeloma (Kahler Disease) - Pipeline by OXIS International Inc, H2 2016 198

Multiple Myeloma (Kahler Disease) - Pipeline by Peptinov SAS, H2 2016 199

Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc, H2 2016 200

Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar SA, H2 2016 201

Multiple Myeloma (Kahler Disease) - Pipeline by Phylogica Ltd, H2 2016 202

Multiple Myeloma (Kahler Disease) - Pipeline by Polyphor Ltd, H2 2016 203

Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Ltd, H2 2016 204

Multiple Myeloma (Kahler Disease) - Pipeline by Progenra Inc, H2 2016 205

Multiple Myeloma (Kahler Disease) - Pipeline by Quimatryx SL, H2 2016 206

Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd, H2 2016 207

Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals SA, H2 2016 208

Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H2 2016 209

Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics Inc, H2 2016 210

Multiple Myeloma (Kahler Disease) - Pipeline by Sellas Inc, H2 2016 211

Multiple Myeloma (Kahler Disease) - Pipeline by Selvita SA, H2 2016 212

Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences Inc, H2 2016 213

Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H2 2016 214

Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 215

Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016 216

Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics Inc, H2 2016 217

Multiple Myeloma (Kahler Disease) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 218

Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H2 2016 219

Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H2 2016 220

Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 221

Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H2 2016 222

Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 223

Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H2 2016 224

Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H2 2016 225

Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics Inc, H2 2016 226

Multiple Myeloma (Kahler Disease) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 227

Multiple Myeloma (Kahler Disease) - Pipeline by Theravectys SA, H2 2016 228

Multiple Myeloma (Kahler Disease) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 229

Multiple Myeloma (Kahler Disease) - Pipeline by Tragara Pharmaceuticals Inc, H2 2016 230

Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H2 2016 231

Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H2 2016 232

Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H2 2016 233

Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2016 234

Multiple Myeloma (Kahler Disease) - Pipeline by Verastem Inc, H2 2016 235

Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H2 2016 236

Multiple Myeloma (Kahler Disease) - Pipeline by Vivolux AB, H2 2016 237

Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H2 2016 238

Multiple Myeloma (Kahler Disease) - Pipeline by XTL Biopharmaceuticals Ltd, H2 2016 239

Assessment by Monotherapy Products, H2 2016 240

Assessment by Combination Products, H2 2016 241

Number of Products by Stage and Target, H2 2016 243

Number of Products by Stage and Mechanism of Action, H2 2016 266

Number of Products by Stage and Route of Administration, H2 2016 290

Number of Products by Stage and Molecule Type, H2 2016 292

Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2016 1054

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..1), H2 2016 1055

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..2), H2 2016 1056

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..3), H2 2016 1057

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..4), H2 2016 1058

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..5), H2 2016 1059

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..6), H2 2016 1060

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..7), H2 2016 1061

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..8), H2 2016 1062

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..9), H2 2016 1063

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..10), H2 2016 1064

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..11), H2 2016 1065

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..12), H2 2016 1066

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..13), H2 2016 1067

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..14), H2 2016 1068

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..15), H2 2016 1069

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..16), H2 2016 1070

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..17), H2 2016 1071

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..18), H2 2016 1072

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..19), H2 2016 1073

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..20), H2 2016 1074

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..21), H2 2016 1075

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..22), H2 2016 1076

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..23), H2 2016 1077

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..24), H2 2016 1078

Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..25), H2 2016 1079

Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2016 1080

Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..1), H2 2016 1081

Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..2), H2 2016 1082

Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..3), H2 2016 1083

Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..4), H2 2016 1084





List of Figures

Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2016 43

Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H2 2016 44

Number of Products under Development by Companies, H2 2016 45

Number of Products under Investigation by Universities/Institutes, H2 2016 59

Comparative Analysis by Late Stage Development, H2 2016 61

Comparative Analysis by Clinical Stage Development, H2 2016 62

Comparative Analysis by Early Stage Products, H2 2016 63

Assessment by Monotherapy Products, H2 2016 240

Assessment by Combination Products, H2 2016 241

Number of Products by Top 10 Targets, H2 2016 242

Number of Products by Stage and Top 10 Targets, H2 2016 242

Number of Products by Top 10 Mechanism of Actions, H2 2016 265

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 265

Number of Products by Top 10 Routes of Administration, H2 2016 289

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 289

Number of Products by Top 10 Molecule Types, H2 2016 291

Number of Products by Stage and Top 10 Molecule Types, H2 2016 291

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus